https://www.live-feeds.com/feed/fda-approves-pancreatic-cancer-drug-that-extends-patients-livesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-approves-pancreatic-cancer-drug-that-extends-patients-liveshttps://www.live-feeds.com/feed/fda-approves-pancreatic-cancer-drug-that-extends-patients-lives#u53836Tue, 01 Sep 2026 10:25:48 +0000The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. The drug targets patients who have already undergone at least one systemic therapy or those ineligible for multiagent systemic therapy. Developed through efforts involving the University of Cincinnati and Dana-Farber, the medication addresses a previously undruggable target. Clinical data indicates the drug nearly doubles median survival from 6.7 months to 13.2 months and blocks tumor growth in over 90% of cases.Why it mattersPancreatic cancer has a high mortality rat https://www.live-feeds.com/feed/fda-approves-pancreatic-cancer-drug-that-extends-patients-liveshttps://www.live-feeds.com/feed/fda-approves-pancreatic-cancer-drug-that-extends-patients-lives#u51362Sat, 29 Aug 2026 06:15:19 +0000The FDA granted expedited approval to Rasonque, a daily oral RAS inhibitor developed by Revolution Medicines and the University of Cincinnati Cancer Center for adults with advanced pancreatic cancer. Clinical trials showed the drug nearly doubled median survival from 6.7 months to 13.2 months. The medication blocks tumor growth in more than 90% of cases. While the drug offers a new treatment path for a disease where 97% of patients die within five years, its high cost has sparked affordability debates in India.Why it mattersPancreatic cancer is one of the deadliest malignancies with historical https://www.live-feeds.com/feed/fda-approves-pancreatic-cancer-drug-that-extends-patients-liveshttps://www.live-feeds.com/feed/fda-approves-pancreatic-cancer-drug-that-extends-patients-lives#u50196Fri, 28 Aug 2026 00:21:16 +0000The FDA has approved daraxonrasib, marketed as RASONQUE, a targeted once-daily pill for advanced pancreatic cancer. The drug was approved more than six months ahead of schedule following trials that nearly doubled median survival to 13.2 months, compared to 6.7 months for patients receiving chemotherapy. Developed by Revolution Medicines with assistance from the University of Cincinnati Cancer Center, the medication is described as a breakthrough for a disease traditionally considered intractable. Anna Berkenblit of the Pancreatic Cancer Action Network stated the organization has never seen a